T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy

Molecular Therapy

Volumn 22, Issue 1, 2014, Pages 102-111

  Yu, Feng ^a   Wang, Xingbing ^a   Guo, Z Sheng ^b   Bartlett, David L ^b   Gottschalk, Stephen M ^a,c   Song, Xiao Tong ^a,c  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 2; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; T LYMPHOCYTE ANTIBODY; TUMOR CELL SURFACE ANTIGEN EPHA2 T CELL ENGAGER ARMED ONCOLYTIC VACCINIA VIRUS; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL KILLING; CELL SURVIVAL; CYTOLYSIS; HUMAN; HUMAN CELL; LUNG CANCER; MULTIPLICITY OF INFECTION; NORMAL HUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR XENOGRAFT; VIRUS REPLICATION;

VACCINIA VIRUS;

ANIMALS; ANTIGENS, CD3; BYSTANDER EFFECT; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE ORDER; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECEPTOR, EPHA2; T-LYMPHOCYTES; VACCINIA VIRUS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891817178     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.240     Document Type: Article

References (50)

1. Russell, SJ, Peng, KW and Bell, JC (2012). Oncolytic virotherapy. Nat Biotechnol 30: 658-670
2. Kelly, E and Russell, SJ (2007). History of oncolytic viruses: Genesis to genetic engineering. Mol Ther 15: 651-659
3. Heo, J, Reid, T, Ruo, L, Breitbach, CJ, Rose, S, Bloomston, M et al. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19: 329-336
4. Breitbach, CJ, Burke, J, Jonker, D, Stephenson, J, Haas, AR, Chow, LQ et al. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477: 99-102
5. Kim, JH, Oh, JY, Park, BH, Lee, DE, Kim, JS, Park, HE et al. (2006). Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 14: 361-370
6. Hwang, TH, Moon, A, Burke, J, Ribas, A, Stephenson, J, Breitbach, CJ et al. (2011). A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 19: 1913-1922
7. Lun, X, Chan, J, Zhou, H, Sun, B, Kelly, JJ, Stechishin, OO et al. (2010). Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther 18: 1927-1936
8. Heo, J, Breitbach, CJ, Moon, A, Kim, CW, Patt, R, Kim, MK et al. (2011). Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: Preclinical and clinical demonstration of combination efficacy. Mol Ther 19: 1170-1179
9. Senzer, NN, Kaufman, HL, Amatruda, T, Nemunaitis, M, Reid, T, Daniels, G et al. (2009). Phase II clinical trial of a granulocyte-macrophage colony-stimulating factorencoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27: 5763-5771
10. Adair, RA, Roulstone, V, Scott, KJ, Morgan, R, Nuovo, GJ, Fuller, M et al. (2012). Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med 4: 138ra77
11. Bollard, CM, Aguilar, L, Straathof, KC, Gahn, B, Huls, MH, Rousseau, A et al. (2004). Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 200: 1623-1633
12. Bollard, CM, Gottschalk, S, Leen, AM, Weiss, H, Straathof, KC, Carrum, G et al. (2007). Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110: 2838-2845
13. Pule, MA, Savoldo, B, Myers, GD, Rossig, C, Russell, HV, Dotti, G et al. (2008). Virusspecific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270
14. Restifo, NP, Dudley, ME and Rosenberg, SA (2012). Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol 12: 269-281
15. Dudley, ME, Wunderlich, JR, Robbins, PF, Yang, JC, Hwu, P, Schwartzentruber, DJ et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854
16. Shafer-Weaver, K, Anderson, M, Malyguine, A and Hurwitz, AA (2007). T cell tolerance to tumors and cancer immunotherapy. Adv Exp Med Biol 601: 357-368
17. Shafer-Weaver, KA, Anderson, MJ, Stagliano, K, Malyguine, A, Greenberg, NM and Hurwitz, AA (2009). Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol 183: 4848-4852
18. Hammond, SA, Lutterbuese, R, Roff, S, Lutterbuese, P, Schlereth, B, Bruckheimer, E et al. (2007). Selective targeting and potent control of tumor growth using an EphA2/ CD3-Bispecific single-chain antibody construct. Cancer Res 67: 3927-3935
19. Lutterbuese, R, Raum, T, Kischel, R, Hoffmann, P, Mangold, S, Rattel, B et al. (2010). T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAFmutated colorectal cancer cells. Proc Natl Acad Sci USA 107: 12605-12610
20. Friedrich, M, Raum, T, Lutterbuese, R, Voelkel, M, Deegen, P, Rau, D et al. (2012). Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 11: 2664-2673
21. Choi, BD, Kuan, CT, Cai, M, Archer, GE, Mitchell, DA, Gedeon, PC et al. (2013). Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci USA 110: 270-275
22. Mack, M, Riethmüller, G and Kufer, P (1995). A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92: 7021-7025
23. Löffler, A, Kufer, P, Lutterbüse, R, Zettl, F, Daniel, PT, Schwenkenbecher, JM et al. (2000). A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95: 2098-2103
24. Bargou, R, Leo, E, Zugmaier, G, Klinger, M, Goebeler, M, Knop, S et al. (2008). Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321: 974-977
25. Topp, MS, Kufer, P, Gökbuget, N, Goebeler, M, Klinger, M, Neumann, S et al. (2011). Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29: 2493-2498
26. Nagorsen, D, Bargou, R, Ruttinger, D, Kufer, P, Baeuerle, PA and Zugmaier, G (2009). Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 50: 886-891
27. Chow, KKH, Naik, S, Kakarla, S, Brawley, VS, Shaffer, DR, Yi, Z et al. (2013). T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther 21:629- 637
28. Frentzen, A, Yu, YA, Chen, N, Zhang, Q, Weibel, S, Raab, V et al. (2009). Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci USA 106: 12915-12920
29. Tysome, JR, Briat, A, Alusi, G, Cao, F, Gao, D, Yu, J et al. (2009). Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther 16: 1223-1233
30. Guse, K, Sloniecka, M, Diaconu, I, Ottolino-Perry, K, Tang, N, Ng, C et al. (2010). Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol 84: 856-866
31. Chalikonda, S, Kivlen, MH, O'Malley, ME, Eric Dong, XD, McCart, JA, Gorry, MC et al. (2008). Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther 15: 115-125
32. Li, J, O'Malley, M, Urban, J, Sampath, P, Guo, ZS, Kalinski, P et al. (2011). Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther 19: 650-657
33. Stephenson, KB, Barra, NG, Davies, E, Ashkar, AA and Lichty, BD (2012). Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of antitumor immunity. Cancer Gene Ther 19: 238-246
34. Filipazzi, P, Valenti, R, Huber, V, Pilla, L, Canese, P, Iero, M et al. (2007). Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25: 2546-2553
35. June, CH, Bluestone, JA, Nadler, LM and Thompson, CB (1994). The B7 and CD28 receptor families. Immunol Today 15: 321-331
36. Fishman, M, Hunter, TB, Soliman, H, Thompson, P, Dunn, M, Smilee, R et al. (2008). Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother 31: 72-80
37. Kaufman, HL, Lenz, HJ, Marshall, J, Singh, D, Garett, C, Cripps, C et al. (2008). Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res 14: 4843-4849
38. Kaufman, HL, Cohen, S, Cheung, K, DeRaffele, G, Mitcham, J, Moroziewicz, D et al. (2006). Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther 17: 239-244
39. Li, G, Wu, X and Zhang, F (2011). Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma. J Cancer Res Clin Oncol 137: 695-703
40. Melero, I, Shuford, WW, Newby, SA, Aruffo, A, Ledbetter, JA, Hellström, KE et al. (1997). Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3: 682-685
41. Lee, H, Park, HJ, Sohn, HJ, Kim, JM and Kim, SJ (2011). Combinatorial therapy for liver metastatic colon cancer: Dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal. J Surg Res 169: E43-e50
42. Kirn, DH, Wang, Y, Le Boeuf, F, Bell, J and Thorne, SH (2007). Targeting of interferonbeta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 4: E353
43. Dower, K, Rubins, KH, Hensley, LE and Connor, JH (2011). Development of Vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression. Antiviral Res 91: 72-80
44. Kakarla, S, Chow, KKH, Mata, M, Schaffer, D, Song, XT, Wu, M-F et al. (2013). Genetically modified T-cells redirected to the tumor stroma for the adoptive immunotherapy of solid tumors. Mol Ther 21:1611-1620
45. Guo, ZS, Thorne, SH and Bartlett, DL (2008). Oncolytic virotherapy: Molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 1785: 217-231
46. Hu, W, Davis, JJ, Zhu, H, Dong, F, Guo, W, Ang, J et al. (2007). Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy. Cancer Biol Ther 6: 1773-1779
47. Thorne, SH, Hwang, TH, O'Gorman, WE, Bartlett, DL, Sei, S, Kanji, F et al. (2007). Rational strain selection and engineering creates a broadspectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 117: 3350-3358
48. Naik, AM, Chalikonda, S, McCart, JA, Xu, H, Guo, ZS, Langham, G et al. (2006). Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates. Hum Gene Ther 17: 31-45
49. Guo, ZS, Naik, A, O'Malley, ME, Popovic, P, Demarco, R, Hu, Y et al. (2005). The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 65: 9991-9998
50. McCart, JA, Ward, JM, Lee, J, Hu, Y, Alexander, HR, Libutti, SK et al. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61: 8751-8757